This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Eugene M. Farber, MD; Dale Pearlman, MD; Elizabeth A. Abel, MD

Arch Dermatol. 1976;112(ANIVERSARY):1679-1688.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Chemotherapeutic agents and pharmacologic principles developed for cancer therapy have assumed importance in the treatment of severe, extensive psoriasis where topical therapy is no longer effective or feasible. One must, however, continually weigh the risk of side effects against possible benefit in the use of these toxic agents. Recent advances, as well as compilation of previously reported clinical trials of methotrexate, azaribine, methoxsalen with ultraviolet light, mycophenolic acid, and hydroxyurea are reported and discussed. The future of systemic chemotherapy for psoriasis lies in the use of randomized double-blind controlled trials to evaluate new agents, the development of new dosage schedules designed to maximize therapeutic index, including possible combination chemotherapy, and the utilization of new routes of administration to provide programmed local tissue levels of effective agents.

Since the time of Paul Ehrlich, the physician who coined the term "chemotherapy" and developed the first alkylating agent, ethylenimine, great strides have been . . . [Full Text PDF of this Article]

Author Affiliations
From the Department of Dermatology, Stanford University Medical Center, Stanford, Calif.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?